Celldex Therapeutics
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases, with lead Phase 3 program barzolvolimab in chronic spontaneous urticaria and planned BLA submission in 2027.
- Company typePublic
- Founded1980
- HeadquartersHampton, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Celldex Therapeutics does
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases. The company's lead program, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that potently inhibits KIT, a receptor tyrosine kinase required for mast cell function and survival, and is advancing through the largest Phase 3 program in antihistamine-refractory chronic spontaneous urticaria (CSU) — the EMBARQ-CSU1 and EMBARQ-CSU2 trials enrolled 1,939 patients across 43 countries and over 500 sites, with topline data expected Q4 2026 and a planned BLA submission in 2027. The second core program, CDX-622, is a novel bispecific antibody that simultaneously neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation, currently in Phase 1b for asthma. Celldex's pipeline also targets cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis, leveraging a proprietary antibody platform with in-house discovery, clinical development, and GMP manufacturing capabilities across four US locations.
Celldex has no marketed products and currently generates no material product revenue. Its business model is a pre-commercial biopharma model funded by periodic public equity raises — most recently a $345 million offering in April 2026 — with future revenue intended to come from US pharmaceutical product sales following regulatory approval of barzolvolimab. The planned go-to-market is enterprise field sales targeting allergists, dermatologists, and immunology specialists, supported by a newly hired Chief Commercial Officer with prior blockbuster immunology launch experience. Celldex is publicly traded on NASDAQ under ticker CLDX, was incorporated in Delaware, and is headquartered in Hampton, New Jersey, with approximately 101–250 employees distributed across clinical, research, manufacturing, and operations sites in New Jersey, Connecticut, and Massachusetts.
Celldex Therapeutics firmographics
Firmographics- Name
- Celldex Therapeutics
- Legal name
- Celldex Therapeutics, Inc.
- Website
- https://celldex.com
- Company type
- Public
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody therapeutics for mast cell-mediated allergic, inflammatory, and autoimmune diseases, with lead Phase 3 program barzolvolimab in chronic spontaneous urticaria and planned BLA submission in 2027.
- Ownership category
- akta.pro rank
Celldex Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
Keywords
Where Celldex Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hampton
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Celldex Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Product Revenue (Future): Celldex is a clinical-stage biotechnology company with no current marketed products or revenue. The company is preparing for commercialization of barzolvolimab with Phase 3 data expected Q4 2026 and planned BLA submission in 2027. Revenue will come from pharmaceutical product sales upon regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Celldex Therapeutics product offering
Product offeringCore offering
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune diseases. Its core programs are barzolvolimab (CDX-0159), a monoclonal antibody inhibitor of KIT that depletes mast cells for chronic spontaneous urticaria and other mast cell-mediated indications, and CDX-622, a bispecific antibody neutralizing TSLP and stem cell factor for asthma and Type 2 inflammatory diseases. Neither product is yet approved or commercialized; barzolvolimab is in Phase 3 with planned BLA submission in 2027.
Product overview
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune disorders. The company operates two core therapeutic programs: barzolvolimab (CDX-0159), a KIT antagonist monoclonal antibody targeting mast cell-mediated diseases including chronic spontaneous urticaria (CSU), cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; and CDX-622, a bispecific antibody targeting TSLP and mast cell depletion for asthma and allergic inflammatory conditions. Barzolvolimab is advancing through Phase 3 trials for CSU with topline data expected Q4 2026 and a planned BLA submission in 2027, while CDX-622 is in Phase 1 development.
Differentiator
Problem solved
Functional benefit
Products and services
- Barzolvolimab (CDX-0159)
Quantifiable outcome
- 64% of CSU patients with angioedema at baseline remained angioedema-free at Week 76 (7 months after completing treatment)
- +4 more outcomes
Companies that use Celldex Therapeutics
Customer profileSegments5 records
Ideal customer profiles3 records
Celldex Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Celldex Therapeutics partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights6 records
Celldex Therapeutics competitors and assessment
Company assessmentDirect peers
- Allakos: Clinical-stage biotech developing antibody therapeutics (lirentelimab) targeting mast cells and eosinophils for inflammatory diseases including chronic urticaria. Directly comparable in mechanism (mast cell modulation) and indication overlap with Celldex.
- Jasper Therapeutics: Clinical-stage biotech developing mast cell-targeted therapies (e.g., briquilimab, an anti-c-Kit antibody) for chronic urticaria and other mast cell-driven diseases. Highly comparable as a direct competitor to barzolvolimab in the mast cell depletion mechanism space.
Emerging players
- argenx: Commercial-stage biotech developing FcRn antagonist efgartigimod (Vyvgart) with expanding indications into chronic inflammatory diseases including chronic urticaria. Comparable as a high-growth antibody company targeting immunological diseases with limited treatment options.
- Arcutis Biotherapeutics: Late-stage dermatology-focused biotech with commercial immunology products (Zoryve). Comparable as a US-focused specialty immunology/dermatology company targeting indications like atopic dermatitis and prurigo nodularis that overlap with Celldex's pipeline expansion plans.
- MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab, a tri-specific Nanobody targeting IL-17A/F and serum albumin, in hidradenitis suppurativa and other inflammatory skin diseases. Comparable as a clinical-stage immunology company pursuing novel antibody mechanisms.
Broad incumbents
- Incyte: Mid-cap biopharma with commercial immunology products (Opzelura cream) and pipeline assets in CSU and other inflammatory diseases. Comparable as a competing antibody developer in mast cell and Type 2 inflammation indications.
- Amgen: Large biopharma with multiple commercial immunology assets (e.g., Tezspire for severe asthma via TSLP pathway, Otezla) that compete or overlap with Celldex's pipeline. Comparable as a major antibody developer in mast cell-mediated and Type 2 inflammatory diseases.
- Regeneron Pharmaceuticals: Large biopharma with Dupixent (dupilumab), which is in late-stage development for chronic spontaneous urticaria - the same indication as Celldex's lead barzolvolimab. Comparable as a developer of antibody-based immunology therapeutics competing in the same end markets.
- Novartis: Markets Xolair (omalizumab), the current standard of care for antihistamine-refractory CSU. Directly comparable as a competitor in the lead indication Celldex is targeting with barzolvolimab.
- Sanofi: Global biopharma co-developing Dupixent with Regeneron, with active CSU program (lirentelimab in-licensed from Allakos for CSU). Comparable as a commercial-stage immunology competitor directly pursuing the barzolvolimab lead indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Celldex Therapeutics social profiles
Digital presenceCelldex Therapeutics compliance and trust
Trust signalCompliance1 record
Celldex Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celldex Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Celldex Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celldex Therapeutics M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celldex Therapeutics
What does Celldex Therapeutics do?
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies for allergic, inflammatory, and autoimmune diseases. Its core programs are barzolvolimab (CDX-0159), a monoclonal antibody inhibitor of KIT that depletes mast cells for chronic spontaneous urticaria and other mast cell-mediated indications, and CDX-622, a bispecific antibody neutralizing TSLP and stem cell factor for asthma and Type 2 inflammatory diseases. Neither product is yet approved or commercialized; barzolvolimab is in Phase 3 with planned BLA submission in 2027.
Is Celldex Therapeutics a public or private company?
Celldex Therapeutics is a public company. It is classified as public and is currently operating.
When was Celldex Therapeutics founded?
Celldex Therapeutics was founded in 1980. It employs 251 to 500 people.
Where is Celldex Therapeutics based?
Celldex Therapeutics is headquartered in Hampton, United States, in the North America region.
How does Celldex Therapeutics make money?
One revenue line is on record: product Revenue (Future).
Who are Celldex Therapeutics's main competitors?
Direct peers on record are Allakos and Jasper Therapeutics. Emerging players are argenx, Arcutis Biotherapeutics and MoonLake Immunotherapeutics. Broad incumbents are Incyte, Amgen, Regeneron Pharmaceuticals, Novartis and Sanofi.
Does Celldex Therapeutics have an API?
No public API is recorded for Celldex Therapeutics.
What industry is Celldex Therapeutics in?
Celldex Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.